Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment

NCT04638647 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04638647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04638647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Recruiting
Start date
December 22, 2020
Completion date
April 4, 2030
Enrollment
1,000 (estimated)
Sites
171

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmunity, inflammation